title: Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.
abstract: Recommended doses of bile-acid binding resins have an established hypocholesterolemic effect, but data on responses to low doses, especially in women and subjects with moderate hypercholesterolemia, are sparse. A double-blind, placebo-controlled, randomized trial of 3 low doses of colestipol hydrochloride was conducted in women and men with moderate hypercholesterolemia. Men and women with plasma low-density lipoprotein (LDL) cholesterol concentrations greater than 4 mmol/liter (155 mg/dl) and triglyceride concentrations less than 2.82 mmol/liter (250 mg/dl) were recruited for the study. Eligible patients (54 women and 98 men) were placed on the American Heart Association step I diet 6 weeks before randomization. Participants were subsequently assigned to 1 of 4 drug treatment groups (placebo, and 5, 10 and 15 g/day of colestipol in 2 divided doses) for an additional 12 weeks. Of the 152 patients randomized, 141 completed all aspects of the study. For the treatment groups--placebo, and 5, 10 and 15 g of colestipol--LDL cholesterol reductions (mmol/liter) were observed respectively (n = 141): 0.10 +/- 0.49 (2.7%), 0.65 +/- 0.41 (16.3%), 0.98 +/- 0.36 (22.8%) and 1.17 +/- 0.47 (27.2%) (p less than 0.001). Similar changes were observed in total cholesterol and apolipoprotein B concentrations. The apolipoprotein B/LDL cholesterol ratio increased significantly with increasing colestipol dosage. Modest but insignificant changes in plasma triglyceride levels occurred, and high-density lipoprotein cholesterol levels remained unchanged. A dose of 5 g/day of colestipol achieved 51% of the LDL cholesterol reduction noted with 15 g/day. Low-dose colestipol therapy is effective in the treatment of patients with moderate hypercholesterolemia.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cholesterol Research Center, Lawrence Berkeley Laboratory, University of California.
authors.forename: H R
authors.initials: HR
authors.lastname: Superko
authors.forename: P
authors.initials: P
authors.lastname: Greenland
authors.forename: R A
authors.initials: RA
authors.lastname: Manchester
authors.forename: N A
authors.initials: NA
authors.lastname: Andreadis
authors.forename: G
authors.initials: G
authors.lastname: Schectman
authors.forename: N H
authors.initials: NH
authors.lastname: West
authors.forename: D
authors.initials: D
authors.lastname: Hunninghake
authors.forename: W L
authors.initials: WL
authors.lastname: Haskell
authors.forename: J L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D003084:Colestipol / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D014481:United States
chemical_list: D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D003084:Colestipol